Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...
Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way.
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.